What is the price-to-earnings ratio of Oryzon Genomics?
The price-earnings ratio of Oryzon Genomics is currently 70.5.
Oryzon Genomics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Comparing Oryzon Genomics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
The P/S ratio is instrumental for investors evaluating Oryzon Genomics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Variations in Oryzon Genomics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
The price-earnings ratio of Oryzon Genomics is currently 70.5.
The price-to-earnings ratio of Oryzon Genomics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Yes, the price-to-earnings ratio of Oryzon Genomics is high compared to other companies.
An increase in the price-earnings ratio of Oryzon Genomics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
A decrease in the price-earnings ratio of Oryzon Genomics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
Some factors that influence the price-earnings ratio of Oryzon Genomics are the company's growth, financial position, industry development, and the overall economic situation.
Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.
The current dividend yield of Oryzon Genomics is .
Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .
Oryzon Genomics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
Oryzon Genomics is assigned to the 'Health' sector.
To receive the latest dividend of Oryzon Genomics from 9/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
The last dividend was paid out on 9/13/2024.
In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.
The dividends of Oryzon Genomics are distributed in EUR.
Our stock analysis for Oryzon Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.